BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Welcome to the 8th Oncolytic Virotherapy Summit: Engineering O
 ncolytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies\n\nRec
 ent years have seen highly promising and rapid advances in the pre-clinic
 al development and clinical evolution of oncolytic virotherapies. They ar
 e increasingly being recognised as a therapy with huge potential to chang
 e the landscape for cancer immunotherapy. In the past 3 months alone\, we
  have witnessed 20 new drugs entering into pre-clinical and clinical phas
 es\, and exciting FDA Fast Track Designation for Candel Therapeutics OV c
 andidate - this community continues to maximize the impact of these hopef
 ul therapies.\n\nUnite with 100+ OV trailblazers across sessions spanning
  Early Discovery\, Translation\, Clinical Development\, Chemistry\, Manuf
 acturing and Controls (CMC) and Regulations to overcome the industry's la
 rgest and critical bottlenecks. Meet your community to hear how they addr
 ess the major challenges facing the industry:\n\nInvestigate the Manufact
 uring Challenges and Approaches to Produce a Successful Oncolytic Virus t
 o Ensure its Quality\, Traceability\, and ReliabilityUnderstand the raw m
 aterials and supply chain management of your oncolytic virus and\, explor
 e the importance of stability of your viral vectors with insights from VY
 RIAD and Circio Bio\n\nOptimize the Immunogenicity of Your Oncolytic Viru
 s Candidate: Maximizing Effectiveness and Minimizing Side Effects in Canc
 er TreatmentDiscuss the current immunogenicity studies to support FIM stu
 dies and assess the safety and efficacy of your oncolytic virus with insi
 ghts from Boehringer Ingelheim and Omios Biologics\n\nReview How to Bridg
 e the Gap Between Pharma\, Biotech and Investors to Facilitate the Growth
  and Development of This FieldAddress the importance of collaboration and
  investment in advancing pharma and biotech innovations\, and discuss the
  strategies for mitigating risks and maximizing returns on investment wit
 h insights from Candel Therapeutics and Valo Therapeutics\n\nDiscover the
  Potential of Using Combination Therapy for Improved Therapeutic Outcomes
 Investigate the innovative combinations of oncolytic viruses with other t
 herapeutic modalities as well as review the current pre-clinical and clin
 ical studies demonstrating anti-tumor efficacy with insights from Replimu
 ne and Oncolys\n\nExplore the Latest Clinical Data and How to Design Bett
 er Clinical Trials to Develop More Effective Oncolytic Virus'sDiscussing 
 the most up to date clinical data on advancements in oncolytic viruses an
 d what are the possible breakthroughs and innovations we may see in the n
 ext year with insights from Lokon Pharma and Calidi Therapeutics\n\nRegis
 ter to Attend - https://ter.li/5drvrm\n\nView Full Event Guide - https://
 ter.li/g866cl\n\n&nbsp\;\n\nTime: 9:00 AM - 6:00 PM\n
DTEND:20231214T180000
DTSTAMP:20260512T220030Z
DTSTART:20231212T090000
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa
 chusetts\, 02116\,
SEQUENCE:0
SUMMARY:Welcome to the 8th Oncolytic Virotherapy Summit: Engineering Oncol
 ytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies\nRecent ye
 ars have...
UID:daae8423-1f48-4af6-94d2-2f79773ec474
END:VEVENT
END:VCALENDAR